Milestone Venture Partners is readying a digital-health investment fund. The VC shop is aiming to raise $150 million from biopharma companies and others to invest in up to 20 early-stage digital health companies.
The 10 biotechs in the latest batch of Y Combinator startups--as well as those that have already graduated from the incubator--will receive $20,000 to spend at Transcriptic's automated life science laboratory.
Biotech backer Versant Ventures has put together a $305 million new purse, cash that will bankroll a new generation of drug developers with a particular focus on Canada's startup scene.
Allena Pharmaceuticals has reeled in a new investor to lead its $25 million B round, which should provide enough money to get its lead drug through a multipronged midstage program and up to the threshold of Phase III. HBM stepped in to lead the pack of the Newton, MA-based biotech's original investors--Frazier Healthcare, Third Rock Ventures and Bessemer Venture Partners--with the help of another new investor, Pharmstandard International.
Seres Health, PMV Pharmaceuticals, Apellis Pharmaceuticals and CANbridge Life Sciences raise $121M in VC cash.
Whatever data Naurex collected from its recently completed Phase IIb study of an NMDA receptor drug for depression, it must have deeply impressed its investment syndicate. Today the company unveiled the news that it has rounded up an $80 million round designed to put the drug through a late-stage pivotal trial.
Seventeen months after rolling out a $30 million Series A round, gene therapy upstart Audentes Therapeutics says it has added a $42.5 million venture round to support its R&D work.
Danish biotech Ascendis Pharma has put together a $60 million D round, cash that'll help get its once-a-week treatment for growth hormone deficiency into late-stage testing.
What makes Woodford such a potent figure is the example he sets in backing global drug development, where even small companies knit together scientific, administrative and support functions from an international cast of players.
Promethera Biosciences has put together €25.3 million ($31.4 million) in equity and loans to hit the gas on its stem cell treatment for rare liver diseases.